Genfit shares rise 5.3% on nangibotide clinical data
Summary
Shares of Genfit increased by 5.3 percent following the release of new clinical data regarding nangibotide. This market movement reflects investor response to the recent updates from the company.
Source: Read the full story at Stock Market News
Disclaimer: This content is for informational and educational purposes only and is not financial, investment or trading advice. Tech & Money Press is not a registered investment adviser or broker-dealer. Trading stocks, options and crypto involves substantial risk, including the loss of your entire investment. Do your own research and consult a licensed professional before making any financial decision. The authors may hold positions in the securities mentioned. News summaries are written with AI assistance from the original publisher's report and may contain errors; always check the original source. Full disclaimer.